Revvity, Inc. filed a Form 10-Q with the Securities and Exchange Commission on August 11, 2026, covering the quarterly period ended July 5, 2026, and reporting condensed consolidated financial results for both the three and six months ended on that date.

Key Highlights

  • Total revenue (three months ended July 5, 2026): $729,688 thousand, compared with $720,284 thousand for the three months ended June 29, 2025, according to the filing.
  • Net income (three months ended July 5, 2026): $51,820 thousand, versus $53,948 thousand in the comparable prior-year quarter, as reported.
  • Six-month total revenue: $1,440,806 thousand for the period ended July 5, 2026, up from $1,385,046 thousand for the six months ended June 29, 2025.
  • Diluted earnings per share from continuing operations: $0.48 for the second quarter and $0.84 for the first half of 2026, per the filing.
  • Total assets as of July 5, 2026: $12,045,834 thousand, with goodwill of $6,607,802 thousand and intangible assets, net, of $2,224,001 thousand.
  • Cash and cash equivalents: $1,022,943 thousand as of July 5, 2026, compared with $919,860 thousand at December 28, 2025.
  • Shares issued and outstanding: 111,584,000 shares of common stock as of July 5, 2026, down from 112,281,000 shares at December 28, 2025.

Revvity's Second Quarter 2026 Operating and Balance Sheet Results

According to the filing, Revvity, Inc. (NYSE:RVTY), a Massachusetts-incorporated company with principal offices in Waltham, reported total revenue of $729,688 thousand for the three months ended July 5, 2026. This consisted of product revenue of $603,411 thousand and service revenue of $126,277 thousand. The company disclosed that total cost of revenue for the quarter was $312,822 thousand, producing operating income from continuing operations of $89,316 thousand. Selling, general and administrative expenses were reported at $278,576 thousand, and research and development expenses were $48,974 thousand.

The filing reported income from continuing operations of $53,481 thousand for the second quarter, after a provision for income taxes of $10,050 thousand. A loss from discontinued operations of $1,661 thousand was also recorded, bringing net income to $51,820 thousand. For the six-month period ended July 5, 2026, the company reported net income of $92,538 thousand, compared with $96,185 thousand for the six months ended June 29, 2025.

On the balance sheet as of July 5, 2026, the filing disclosed total stockholders' equity of $7,228,758 thousand. Long-term debt stood at $2,633,094 thousand, and the current portion of long-term debt was $572,156 thousand. The company also disclosed that during the six months ended July 5, 2026, it paid dividends of $0.07 per common share in each of two quarters and repurchased shares, with common stock outstanding declining from 112,281,000 shares at December 28, 2025 to 111,584,000 shares at July 5, 2026.

What Was Disclosed

Revvity's 10-Q for the period ended July 5, 2026 disclosed condensed consolidated income statements, balance sheets, and statements of stockholders' equity, covering both quarterly and six-month results for the life sciences and diagnostics company, which is listed on the New York Stock Exchange.